Phase 3 Readout
IDYA: Phase 3 Topline: Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenf
December 16, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 16, 2026
- Company
- IDEAYA Biosciences, Inc. (IDYA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenf
- Indication
- Dravet Syndrome